文献速递免疫规划

J型副黏病毒载体HIV疫苗在小鼠中诱导体液和细胞免疫应答

A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
PubMed 文献 · Vaccine · 2024-03-04

研究以J型副黏病毒(JPV)为载体表达HIV包膜糖蛋白(env),替换JPV小疏水(SH)基因构建rJPV-env,经鼻内免疫小鼠诱导抗HIV-gp120 IgG抗体。进一步比较同源与异源初免/加强方案,rJPV-env/rPIV5-env异源初免/加强诱导最强的体液和细胞应答;加入第三剂后,病毒载体初免组HIV-env特异性细胞应答高,其中rJPV-env/rPIV5-env/VLP组最高。

要点

  • 鼻内接种rJPV-env诱导小鼠产生抗HIV-gp120 IgG抗体。
  • rJPV-env/rPIV5-env异源初免/加强方案的体液和细胞应答最强。
  • 三剂免疫后rJPV-env/rPIV5-env/VLP组HIV-env特异性细胞应答最高。

核心结论

  • 病毒载体HIV-env疫苗与HIV-Gag-Env病毒样颗粒(VLP)的异源组合可在小鼠中诱导高水平抗HIV体液和细胞应答。

研究设计与样本

  • 研究用J型副黏病毒(JPV)为载体,将JPV小疏水(SH)基因替换为HIV-env,构建rJPV-env。
  • 小鼠经鼻内免疫rJPV-env,并比较rJPV-env、rPIV5-env和HIV-Gag-Env VLP的同源与异源初免/加强方案。

主要发现

  • 鼻内rJPV-env免疫诱导小鼠产生抗HIV-gp120 IgG抗体。
  • rJPV-env/rPIV5-env异源初免/加强方案诱导最强的体液和细胞应答。
  • 加入第三剂后,病毒载体初免组小鼠HIV-env特异性细胞应答高,rJPV-env/rPIV5-env/VLP组最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human immunodeficiency virus (HIV) infects and depletes CD4+ T-cells, resulting in Acquired Immunodeficiency Syndrome (AIDS) and death. Despite numerous clinical trials, there is no licensed HIV vaccine. The HIV envelope glycoprotein (env) is a major target for vaccine development, especially for the development of antibody-mediated protection. In this study, we used J paramyxovirus (JPV) as a viral vector to express HIV-env. We replaced the JPV small hydrophobic (SH) gene with HIV-env (rJPV-env). Intranasal rJPV-env immunization induced anti-HIV-gp120 IgG antibodies in mice. Furthermore, we examined the immunogenicity of homologous and heterologous prime/boost regimens with rJPV-env, parainfluenza virus 5 (rPIV5)-vectored HIV-env, and HIV-Gag-Env virus-like particles (VLPs). The rJPV-env/rPIV5-env heterologous prime/boost regimen induced the strongest humoral and cellular responses. Introducing a third dose of immunization, mice that received a viral-vectored prime had high levels of HIV-env-specific cellular responses, with group rJPV-env/rPIV5-env/VLP having the highest. Together, this work indicates that a heterologous combination of viral-vectored HIV-env vaccines and a HIV-Gag-Env VLP induces high levels of humoral and cellular responses against HIV in mice.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Beavis AC, Dienger-Stambaugh K, Briggs K, et al. A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice. Vaccine. 2024. PMID: 38443277. doi:10.1016/j.vaccine.2024.02.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。